Browse > Article
http://dx.doi.org/10.13045/acupunct.2014009

Effects of Paljeong-san Pharmacopuncture on Experimental Rat Model of Benign Prostatic Hyperplasia  

Kim, Chae Weon (Department of Acupuncture & Moxibustion Medicine, College of Oriental Medicine, Sangji University)
Lee, Kwang Ho (Department of Acupuncture & Moxibustion Medicine, College of Oriental Medicine, Sangji University)
Publication Information
Journal of Acupuncture Research / v.31, no.1, 2014 , pp. 95-103 More about this Journal
Abstract
Objectives : The aim of this study is to evaluate the effect of Paljeong-san pharmac-opuncture(PJS) on the rat model of benign prostatic hyperplasia(BPH). Methods : Rats were divided into 5 groups, with 6 rats in each group. The 5 groups included sham-operated group(sham group), BPH model group(BPH group), finasteride-treated group (fina group), PJS-treated groups(PJS 10 and PJS 100 group). Testosterone was injected subcutaneously to the castrated rats except sham group for BPH model. During 4-week experimental period, finasteride(5 mg/kg) was administrated orally once daily in fina group, PJS in PJS 10(10 mg/kg) and PJS 100(100 mg/kg) group and normal saline in sham and BPH group were injected subcutaneously once daily at Jungwan($CV_{12}$). We checked prostate weights, serum concentration of dihydrotestosterone(DHT), morphologic changes of the prostate, and the amount of expression of the proliferating cell nuclear antigen(PCNA) and $5{\alpha}$-reductase gene to evaluate the effect of PJS after 4-week experimental period. Results : 1. PJS and finasteride treatment reduced prostate weights comparing with BPH group, but PJS-treated groups showed no significant changes, unlikely fina group. 2. PJS-treated groups showed significant degreases in concentration of DHT. 3. PJS-treated groups showed significant degreases concentration-dependently in the amount of expression of the PCNA and $5{\alpha}$-reductase gene. 4. PJS treatment showed shrinking of thickness in the prostatic epithelial tissue. Conclusions : PJS has the effects that improve the symptoms of BPH through inhibiting proliferation of the prostatic tissues.
Keywords
Benign prostatic hyperplasia; Paljeong-san; Pharmacopuncture; Finasteride;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Yang CY, Song HS. Bee Venom Inhibits Prostate Cancer Growth in LNCaP Xenografts via Apoptosis. J Pharmacopuncture. 2010 ; 13(1) : 15-35.
2 Shin JM, Song HS. Bee Venom Inhibits DU-145 Human Prostate Cancer Cell Growth Through Inactivation of NF-${\kappa}B$. J Korean Acupuncture & Moxibustion Society. 2011 ; 28(3) : 101-10.
3 Oh HJ, Song HS. Bee Venom Inhibits PC-3 Cell Proliferation Through Induction of Apoptosis Via Inactivation of NF-${\kappa}B$. J Korean Acupuncture & Moxibustion Society. 2010 ; 27(3) : 1-13.
4 Hur KY, Song HS. Bee Venom Inhibits DU-145 Cell Proliferation Through Induction of Apoptosis. J Korean Acupuncture & Moxibustion Society. 2011 ; 28(3) : 111-9.
5 Woo JH, Kang JY, Kim EK et al. The effect of short term dutasteride therapy on microvessel density in benign prostatic hyperplasia. Korean J Urol. 2008 ; 49(6) : 515-9.   DOI   ScienceOn
6 Lourenco T, Pcickard R, Vale L et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ. 2008 ; 337 : a1662.   DOI
7 Doo HK. Donguisingyehagyeongu. Seoul : Kyung Hee University Press. 1994 : 359.
8 Jin S. Taepyeonghyeminhwajegugbang. Taipei : Seonpung Publisher. 1984 : 175.
9 Heo J. Donguibogam. Seoul : Donguibogam. 2010 :
10 Professors of Department of Formula Science in College of Korean Medicine. Formula Science. Seoul : Yeongnimsa. 1999 : 497.
11 Committee on Compilation of Textbook of Korean Society for Acupuncture & Moxibustion. Acupuncture & Moxibustion. Paju : Jipmoondang Publishing Company. 2008 : 306.
12 Rim HK, Rim JS, Moon HB. A Study on the Relationship between Histologic Composition and Clinical Symptoms in Benign Prostatic Hyperplasia. Korean J Urol. 1994 ; 35(3) : 230-6.
13 McNeal JE. The prostate and prostatic urethra: a morphologic synthesis. J Urol. 1972 ; 107(6) : 1008-16.
14 McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978 ; 15(4) : 340-5.
15 Kim JG, Cho KS, Ahn HJ. The Evaluation of Correlation between the Histologic Composition of BPH and TRUS Findings. Korean J Urol. 1998 ; 39(1) : 51-6.
16 Jung SI, Oh BR, Ryu SB. Assessing the Effect of Finasteride by Prostate Tissue Composition. Korean J Urol. 2001 ; 42(12) : 1278-83.
17 Chae SJ, Song HS. The Effects of Cobrotoxin on NF-$\kappa{B}$ Activation in Human Prostatic Cancer Cell Line(PC-3). J Korean Acupuncture & Moxibustion Medicine Society. 2005 ; 22(5) : 37-48.
18 Korean Society for Sexual Medicine and Andrology. Textbook of Andrology. Seoul : Koonja. 2003 ; 542, 557-65.
19 Hong SJ. Benign prostatic hyperplasia: Multiple factors for prostate tissue change with aging. Korean J Urol. 2005 ; 46(6) : 547-54.
20 Lee DH, Lee JS, Kim YS. The effects of Lygodium japonicum on experimental rat model of benign prostatic hyperplasia. J Korean Orient Int Med. 2010 ; 31(3) : 457-66.
21 Wei J, Calhoun E, Jacobsen S. Urologic disease in America project: benign prostatic hyperplasia. J Urol. 2005 ; 173(4) : 1256-61.   DOI   ScienceOn
22 Paloma AM, Clemens B, Angelika R et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. PNAS. 2009 ; 106(8) : 2859-63.   DOI   ScienceOn
23 Carson C III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003 ; 61(4 Supple 1) : 2-7.
24 Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 alphareductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002 ; 19(6) : 413-25.   DOI   ScienceOn
25 McConnell J, Roehrborn C, Bautista O et al. Benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology. 2003 ; 62(3 Supple 1) : 15-23.
26 Lee HG, Park YI, Jo SR. Clinical results of transurethral Electro-Vaporization of the prostate. Korean J Urol. 2001 ; 42(8) : 804-8.
27 Amy E Krambeck, Shelly E Handa, James E Lingeman. Experience with more than 1,000 Holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2013 ; 189(4) : 1415-20.   DOI   ScienceOn
28 Doo HK. Donguisingyehag. Seoul : Seongbosa. 2003 : 705-8.
29 Doo HK. Imsangsingyehagyeongu. Seoul : Seongbosa. 1995 : 452.
30 Hyun MK, Sin WY, Choi EY et al. A case of intractable hiccup treated with Paljung-san. J Korean Orient Int Med. 2005 ; 25(2) : 506-11.
31 Kim SM, Yoo DY. A case report of the effect of Paljeongsna on the female urethral syndrome. Korean J Obstet Gynecol. 2007 ; 20(4) : 225-33.
32 Song MK, Park SH, Kang JS et al. Report of four cases of Paljung-san on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Korean Oriental Med. 2010 ; 31(1) : 153-61.
33 AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). chapter 1: Diagnosis and treatment recommendations. J Urol. 2003 ; 170 : 530-47   DOI   ScienceOn
34 Lim CY, Kim MH, Lee GS et al. Beneficial effect of Paljeong-san pharmacopuncture treatment combined with peritoneal injection on Glycerolinduced acute renal failure in rabbits. J Korean Pharm Sci. 2010 ; 13(3) : 73-80.
35 Lee SY, Kim MH, Cho SI et al. The effect of Paljeong-San pharmacopuncture treatment on Glycerol-induced acute renal failure in rats. The Journal of Daejeon Oriental Medicine. 2012 ; 21(1) : 163-74.
36 American Urological Association. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia(BPH). American Urology Association Education and Research, Inc. 2010 : 2-8.
37 The Korean Urological Association. The Urology. Seoul : Korea Medical Box Publisher. 2001 : 307-9.
38 Chung BH. Medical management for benign prostatic hyperplasia. Korean J Urol. 2007 ; 48(3) : 233-43.   DOI   ScienceOn